In light of recent research suggesting that the shingles vaccine might reduce the risk of dementia by up to 20%, whether it plans to (a) ex…

Recent research suggests vaccination for shingles with the live attenuated herpes zoster vaccine (Zostavax®) could be linked to a reduction in the risk of developing dementia.In the UK, Zostavax®, a live vaccine, was routinely offered to those eligible for the NHS shingles programme and not contraindicated to the vaccine.In February 2019, the Joint Committee on Vaccination and Immunisation recommended that Shingrix® a non-live vaccine, should replace Zostavax® in the routine programme and since 1 September 2023, all newly eligible individuals have been offered the non-live shingles vaccine Shingrix®.